REFLECTIONS OF 16 YEARS AT THE KAVI INSTITUTE OF CLINICAL RESEARCH

It seems a lifetime ago since I joined KAVI as a scrawny pimply young doctor on 12th January 2004. After working 7 years at a busy A/E department, I knew clinical practice wasn’t for me. I had tried my hand in ENT surgery but that didn’t work out either. Somewhat lost and disillusioned, I needed out but didn’t know what I wanted. Joining KAVI was a stepping stone to the unknown. Little did I know then that in KAVI I would find the true purpose of my career in medicine in the field of clinical research.

Professor Kindrachuk presenting on Incidental and Reservoir hosts of the Ebola Virus at KAVI-ICR Journal Club

The New Year started on 24th January 2020 for KAVI-ICR Journal club with Professor Jason Kindrachuk from the Department of Medical Microbiology & Infectious Diseases, University of Manitoba, Presenting on Ebola Virus. The presentation was titled 'Identifying the molecular determinants underlying Ebola virus persistence in incidental and reservoir hosts.' The KAVI-ICR Journal club brings together scientists and students twice a month to listen to presentations of various projects.

Dr. Mureithi presents KAVI-ICR ground-breaking Mucosal Immunology work at Imperial College London

Dr. Marianne Mureithi presented KAVI-ICR ground-breaking Mucosal Immunology work titled “Defining HIV-1 interactions at the Mucosa”  at the emerging techniques for investigating mucosal immunity and delivery of therapies symposium” held at the Anthony de Rothschild Lecture Theatre, St Mary’s Campus Imperial College London, UK on August 5th, 2019.

IAVI-W001 Study Launched at the KAVI-Institute of Clinical Research

On 24th September 2019, the first volunteer was enrolled in the IAVI-W001 study at the KAVI-Institute of Clinical Research (KAVI-ICR) of the University of Nairobi.  The occasion marks the beginning of the 12th HIV vaccine clinical trial to be conducted at KAVI-ICR since 2001. This is a first-in-human study that uses a Native-trimer HIV envelope design that will hopefully stimulate broadly neutralizing antibodies against HIV.